Form 8-K - Current report:
SEC Accession No. 0001193125-19-279695
Filing Date
2019-10-31
Accepted
2019-10-31 08:04:47
Documents
14
Period of Report
2019-10-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d816314d8k.htm   iXBRL 8-K 26868
2 EX-99.1 d816314dex991.htm EX-99.1 187889
6 GRAPHIC g816314g1031062146276.jpg GRAPHIC 5520
  Complete submission text file 0001193125-19-279695.txt   366156

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgen-20191031.xsd EX-101.SCH 3083
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgen-20191031_lab.xml EX-101.LAB 18909
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgen-20191031_pre.xml EX-101.PRE 11872
14 EXTRACTED XBRL INSTANCE DOCUMENT d816314d8k_htm.xml XML 3513
Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Filer) CIK: 0000730272 (see all company filings)

EIN.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-14656 | Film No.: 191182166
SIC: 2836 Biological Products, (No Diagnostic Substances)